Emergent BioSolutions Launches FDA-Approved 6- and 24-Pack NARCAN; Q4 Call Feb 26
Emergent BioSolutions secured FDA approval for supplemental new drug applications introducing 6-count and 24-count NARCAN® OTC nasal spray multipacks, enabling large-scale distribution flexibility for community and high-volume partners. The company also scheduled its fourth-quarter and full-year 2025 earnings conference call for February 26 at 5:00 PM Eastern, accessible via webcast.
1. FDA Approval for NARCAN Multipack Configurations
The FDA has approved Emergent’s supplemental New Drug Application for over-the-counter NARCAN Nasal Spray in 6-count and 24-count multipack formats, expanding the product suite beyond single-dose packaging.
2. Multipack Distribution and Market Impact
These new configurations are designed to improve cost-effectiveness and streamline bulk distribution for community programs, multi-site organizations and other high-volume naloxone distributors, complementing existing offerings.
3. Scheduled Q4 and Full-Year 2025 Earnings Call
Emergent will present its fourth-quarter and full-year 2025 financial results on February 26 at 5:00 PM Eastern via a live webcast and telephone conference call with advance registration required.